DICE Therapeutics to Participate at Upcoming Investor Conferences

Rhea-AI Summary

DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company specializing in oral therapeutics for chronic diseases, announced participation in two major investor conferences. The SVB Securities Global Biopharma Conference features a fireside chat on February 14, 2023, at 2:20 p.m. ET, followed by the 43rd Annual Cowen Healthcare Conference dermatology panel on March 7, 2023, at 12:50 p.m. ET. Live and archived webcasts of these presentations will be available for 90 days on the company’s website. DICE focuses on developing novel oral candidates targeting immunology, aiming for comparable effectiveness to existing biologics.

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced management will participate at the following investor conferences:

• SVB Securities Global Biopharma Conference 2023 
  Fireside Chat: Tuesday, February 14 at 2:20 p.m. ET

• 43rd Annual Cowen Healthcare Conference 
  Dermatology Panel: Tuesday, March 7 at 12:50 p.m. ET

Live and archived webcasts of the presentations will be accessible under “News & Events” in the Investors section of the company's website for 90 days after the applicable event.

About DICE Therapeutics, Inc.
DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Contacts:

Media:
Katie Engleman, 1AB
katie@1abmedia.com

Investors:
investors@dicetx.com

FAQ

What is the date and time of the DICE Therapeutics fireside chat at the SVB Securities Global Biopharma Conference?

The fireside chat will take place on February 14, 2023, at 2:20 p.m. ET.

When will DICE Therapeutics participate in the Cowen Healthcare Conference?

DICE Therapeutics will participate in the Cowen Healthcare Conference on March 7, 2023, at 12:50 p.m. ET.

Where can I access the webcasts of DICE Therapeutics' presentations?

Live and archived webcasts can be accessed under the 'News & Events' section of the company's website for 90 days after each event.

What is the focus of DICE Therapeutics' drug development?

DICE Therapeutics focuses on developing oral therapeutics for chronic diseases, particularly in immunology.

What are the lead therapeutic candidates being developed by DICE Therapeutics?

DICE's lead candidates are oral antagonists targeting the pro-inflammatory molecule IL-17, among other targets for inflammatory diseases.